List of Excipients in Branded Drug INFANTS ADVIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	INFANTS ADVIL	ibuprofen	0573-0191	ACETIC ACID
Haleon US Holdings LLC	INFANTS ADVIL	ibuprofen	0573-0191	BUTYLATED HYDROXYTOLUENE
Haleon US Holdings LLC	INFANTS ADVIL	ibuprofen	0573-0191	CARBOXYMETHYLCELLULOSE SODIUM

Infants Advil Excipient Strategy, Regulatory Position, and Commercial Opportunities

Last updated: August 24, 2026

Infants' Advil is an ibuprofen oral suspension marketed for pediatric fever and pain relief. Its commercial value depends less on active-ingredient exclusivity than on excipient execution: dose accuracy, palatability, physical stability, preservative performance, age-appropriate packaging, and differentiation from children's ibuprofen products.

The main opportunity is a premium pediatric formulation with improved taste, lower dosing volume, preservative or sugar reduction, and a delivery system that reduces administration errors. The principal constraints are FDA over-the-counter requirements, ibuprofen tolerability, excipient suitability for infants and young children, and the limited patentability of conventional suspensions.

What is Infants' Advil and how is it regulated?

Infants' Advil is a concentrated ibuprofen oral suspension. The commonly marketed U.S. concentration is 50 mg per 1.25 mL, equivalent to 40 mg/mL. The product is intended for children under pediatric dosing instructions and is administered with an oral syringe or dosing device.

Attribute	Product position
Brand	Infants' Advil
Active ingredient	Ibuprofen
Dosage form	Oral suspension
Common concentration	50 mg per 1.25 mL
Therapeutic category	Pediatric analgesic and antipyretic
U.S. regulatory route	OTC ibuprofen monograph framework and product labeling requirements
Primary formulation issues	Taste, sedimentation, redispersibility, preservative protection, dosing accuracy
Primary commercial competitors	Children's Advil, Motrin Infant Drops, generic infant ibuprofen suspensions, store-brand products
Key product differentiator	Concentrated dose in a small administration volume

Ibuprofen is an established active ingredient with broad generic availability. The commercial product is therefore dependent on brand recognition, retail placement, packaging, formulation quality, and consumer trust rather than active-ingredient exclusivity.

What excipients are used in Infants' Advil?

Infants' Advil labeling identifies excipients typical of a concentrated pediatric ibuprofen suspension. The formulation has used suspending agents, viscosity modifiers, buffering agents, preservatives, surfactants, sweeteners or humectants, flavoring, and purified water. The exact inactive-ingredient list should be taken from the current product label because manufacturers can revise excipient systems without changing the active ingredient or therapeutic claim.[1]

Typical functional categories include:

Excipient function	Potential ingredient class	Commercial purpose
Suspending system	Microcrystalline cellulose and carboxymethylcellulose sodium	Limits settling and supports redispersion
Viscosity control	Hypromellose or related cellulose polymer	Improves dose uniformity and mouthfeel
Wetting and dispersion	Polysorbate 80 or nonionic surfactant	Helps disperse hydrophobic ibuprofen
Buffering	Citric acid and sodium citrate	Controls pH and supports stability
Preservation	Sodium benzoate or another permitted preservative	Controls microbial growth in a multidose aqueous product
Sweetness and mouthfeel	Glycerin, sucrose, or alternative sweetener system	Masks bitterness and reduces harshness
Flavor	Fruit flavor system	Improves pediatric acceptance
Vehicle	Purified water	Provides the aqueous suspension medium

Ibuprofen has low water solubility. A concentrated liquid product must therefore maintain a uniform suspension rather than rely on complete dissolution. That requirement drives the selection of cellulose polymers, wetting agents, particle-size controls, and mixing conditions.

How should an excipient strategy be designed for pediatric ibuprofen?

A robust strategy should optimize five performance attributes: dose uniformity, physical stability, microbial control, palatability, and manufacturability.

1. Suspending system

The suspension must redisperse rapidly after storage without forming a hard cake. Excessive viscosity can improve physical stability but can make the product difficult to pour or draw into an oral syringe. A low-viscosity formulation can improve administration but increases the risk of settling and dose variability.

A cellulose-based structured vehicle is commercially practical because it is familiar to regulators and can support a broad manufacturing platform. The development target should include:

• Redispersion after defined periods of upright and inverted storage.
• Dose uniformity from the first, middle, and final withdrawals.
• Stable rheology across normal storage temperatures.
• Compatibility with oral syringes and dosing cups.
• No excessive foaming during shaking.

2. Taste masking

Ibuprofen has a strong bitter taste. Taste masking is often the most important consumer-facing excipient problem. A conventional flavor and sweetener system may be adequate for some children but can fail in younger patients or after repeated dosing.

Potential approaches include:

• Increasing flavor coverage without creating an excessively acidic or artificial taste.
• Using a sweetener combination rather than relying on a single sweetener.
• Applying polymeric taste masking to ibuprofen particles.
• Using ion-exchange or lipid-based coating technologies.
• Reducing the exposed drug surface area through particle engineering.
• Developing a less bitter ibuprofen salt or solid dispersion, subject to regulatory acceptability.

The strongest commercial opportunity is not simply "better flavor." It is a formulation that reduces bitterness while preserving suspension stability and rapid dose release.

3. Preservative strategy

A multidose aqueous suspension generally requires antimicrobial protection unless the container-closure system and use pattern provide another validated control strategy. Sodium benzoate is widely used in oral liquid products, but its suitability depends on pH, concentration, microbial challenge performance, and total daily exposure.

A reformulation program could evaluate:

• Preservative concentration and pH optimization.
• Preservative-free packaging using unit-dose sachets, ampoules, or blow-fill-seal containers.
• Reduced-volume multidose packaging with an integrated delivery device.
• Antimicrobial container systems, where permitted and supported by data.
• Compatibility with flavors, polymers, and closure materials.

Preservative-free positioning can support premium pricing, but it can also raise packaging costs and complicate manufacturing. The commercial case is strongest when preservative reduction is combined with a clear consumer benefit, such as single-dose convenience or improved suitability for sensitive children.

4. Sugar and allergen positioning

Parents increasingly scrutinize sugar, dyes, allergens, and artificial ingredients. A sugar-free product can appeal to caregivers managing repeated dosing or children with dietary restrictions. It may also support dental-health positioning, although product claims must comply with applicable labeling requirements.

Sugar reduction can create technical problems:

• Loss of sweetness and mouthfeel.
• Greater perception of ibuprofen bitterness.
• Increased need for polyols or high-intensity sweeteners.
• Possible changes in viscosity and microbial behavior.
• Flavor instability during shelf life.

A successful sugar-free formulation should be evaluated against the incumbent product in blinded pediatric sensory testing. A "free-from" claim without acceptable taste is unlikely to generate repeat purchases.

5. Dosing-device compatibility

The dosing device is part of the product system. A 50 mg per 1.25 mL concentration reduces administration volume, but concentrated dosing increases the consequences of a measurement error.

Commercially relevant device improvements include:

• A low-dead-space oral syringe.
• A dose-lock mechanism that reduces incorrect volume selection.
• A bottle adapter that improves syringe filling.
• A tactile or color-coded dose scale.
• Packaging that prevents use of household teaspoons.
• Unit-dose delivery for travel and daycare use.

Device patents can provide stronger differentiation than conventional excipient patents. The patent claim set may cover the bottle adapter, syringe geometry, dose-selection mechanism, closure, or combination of formulation and device.

What formulations could create new commercial opportunities?

Preservative-free infants' ibuprofen suspension

A preservative-free product could target caregivers seeking a simpler excipient profile. The likely format would be unit-dose packaging or a highly controlled multidose system. The tradeoff is higher packaging cost, more complex filling operations, and potentially greater waste.

Sugar-free and dye-free formulation

A sugar-free, dye-free product could compete in premium pediatric analgesics. The formulation must replace sweetness and flavor coverage without increasing bitterness or creating a chalky mouthfeel.

Lower-volume concentrated formulation

A more concentrated suspension could reduce administration volume, but the dosing risk increases as concentration rises. FDA labeling, device calibration, and human-factors testing would become central development requirements.

Fast-redispersing suspension

A product that requires fewer shakes and redisperse rapidly could reduce dose variability and improve caregiver convenience. This benefit may be protectable through particle engineering, rheology, and manufacturing controls.

Unit-dose sachets or blow-fill-seal containers

Unit-dose packaging can support preservative-free claims, travel use, and improved hygiene. It also creates a differentiated format for hospitals, pharmacies, daycare settings, and e-commerce multipacks.

Alternate pediatric ibuprofen delivery systems

Chewable tablets, orally disintegrating tablets, mini-tablets, and lipid-based oral dispersions could target children who resist liquid dosing. These products would compete with conventional suspensions but may carry greater formulation and pediatric acceptability risk.

What FDA regulatory requirements apply to Infants' Advil excipients?

The active ingredient and dosage form fall within the U.S. OTC framework for internal analgesic, antipyretic, and antirheumatic drug products. The regulatory analysis must address the final formulation, not merely the historical use of each excipient.

Key requirements include:

1. Each inactive ingredient must be appropriate for the route, dosage form, concentration, and target pediatric population.
2. Excipient exposure should be evaluated against the FDA Inactive Ingredient Database and relevant safety information.[2]
3. The formulation must meet applicable quality, stability, microbial, and container-closure requirements.
4. Pediatric labeling must comply with the applicable OTC monograph and Drug Facts requirements.
5. The dosing device must deliver the labeled dose accurately and consistently.
6. Flavors, colors, preservatives, and sweeteners must be properly identified and supported.
7. Any material formulation change may require regulatory assessment, stability data, and updated labeling.

The FDA Inactive Ingredient Database is useful for identifying precedent, but database presence does not eliminate the need to justify the selected concentration and pediatric exposure. FDA guidance also emphasizes careful consideration of excipients in pediatric drug products because children can have different exposure patterns, swallowing capabilities, and tolerability profiles than adults.[2,3]

What patents protect Infants' Advil?

The core ibuprofen molecule is long out of patent protection. Conventional excipients such as cellulose polymers, citrate buffers, glycerin, common flavors, and sodium benzoate generally do not create a meaningful blocking patent position when used in routine combinations.

The commercially relevant patent opportunities are more likely to involve:

Potential patent area	Patent strength
Ibuprofen molecule	None for ordinary commercial entry
Conventional suspension composition	Low unless unusually narrow and technically supported
Taste-masked ibuprofen particles	Moderate to high if performance data support non-obvious claims
Specific particle-size distribution	Moderate if linked to stability or taste results
Preservative-free multidose system	Moderate if container and formulation claims are integrated
Oral syringe and bottle adapter	Moderate to high depending on claim scope
Unit-dose packaging	Moderate, but design-around risk is significant
Manufacturing process	Moderate if it controls particle coating, dispersion, or dose uniformity
Combination product involving formulation and device	Potentially strong if claims are properly drafted

A defensible patent portfolio would include composition claims, particle or coating claims, process claims, and device claims. A single broad claim to "ibuprofen, a suspending agent, a sweetener, and flavor" would face substantial validity and prior-art risk.

What is the Orange Book status of Infants' Advil?

Infants' Advil is generally commercialized as an OTC ibuprofen product rather than as a conventional new chemical entity with a valuable Orange Book patent estate. OTC monograph products do not create the same patent-certification profile as prescription drugs approved under a full NDA.

The practical consequences are:

• No meaningful molecule-level exclusivity.
• No conventional NCE exclusivity period.
• Generic and store-brand competition is legally feasible.
• Formulation and device patents may still create litigation or design-around issues.
• A competitor may enter with a materially different excipient system while relying on the same OTC active ingredient framework.

The relevant competitive barrier is therefore execution and brand economics, not Orange Book exclusivity.

When does Infants' Advil lose exclusivity?

Infants' Advil has no commercially significant remaining exclusivity tied to the ibuprofen active ingredient. Generic ibuprofen pediatric suspensions and private-label products can compete subject to applicable FDA requirements.

Brand protection may still arise from:

• Trademarks and trade dress.
• Product-specific formulation patents, if any remain enforceable.
• Device patents.
• Manufacturing know-how.
• Retail distribution agreements.
• Consumer recognition and pharmacist recommendation.
• Packaging and merchandising.

These protections do not prevent broad market entry in the same way as a valid composition-of-matter patent.

Which companies compete with Infants' Advil?

The competitive field includes brand, generic, private-label, and alternative dosage-form products.

Competitor group	Representative products or channels	Main competitive lever
Brand ibuprofen	Children's Advil, Motrin infant products	Brand trust and retail distribution
Store brands	Pharmacy, mass-market, and club-store ibuprofen suspensions	Lower price
Generic manufacturers	Pediatric ibuprofen oral suspensions	Regulatory efficiency and supply
Acetaminophen brands	Infants' Tylenol and store brands	Alternative active ingredient
Specialty pediatric products	Dye-free, sugar-free, preservative-reduced products	Excipient positioning
Pharmacy and e-commerce private label	Retailer-controlled products	Margin and channel exclusivity

Acetaminophen is the principal therapeutic substitute, although it is not pharmacologically identical to ibuprofen. A premium ibuprofen product must communicate accurate age, dose, and administration instructions without encouraging unnecessary switching between active ingredients.

What generic entry risks exist for Infants' Advil?

Generic entry risk is high because ibuprofen is mature, widely used, and available in standard oral liquid formats. The main competitive threats are:

• Lower-priced store brands.
• Retailer-exclusive products.
• Generic products using the same concentration.
• Dye-free or sugar-free alternatives.
• Private-label products with improved dosing devices.
• Supply-based price competition during pediatric illness seasons.

A differentiated formulation can reduce direct substitution, but a competitor can often design around an excipient claim by changing the flavor system, suspending polymer, preservative, or packaging format.

How strong is the patent estate for an Infants' Advil reformulation?

A conventional excipient reformulation would have weak-to-moderate patent strength. Stronger protection is possible when the formulation solves a measurable technical problem and the claims are supported by comparative data.

The most defensible claim categories are:

1. A taste-masked ibuprofen particle with defined coating composition and dissolution profile.
2. A suspension with a specified redispersion time and dose-uniformity range.
3. A preservative-free multidose package with validated microbial-control performance.
4. A formulation-device combination that limits dosing error.
5. A manufacturing process that creates a reproducible particle-size or coating distribution.

Patent prosecution should avoid relying solely on ingredient lists. Unexpected results, comparative taste data, storage data, and dose-delivery performance would materially improve validity and enforcement prospects.

What licensing deals could support an Infants' Advil opportunity?

Potential licensing targets include:

• Taste-masking technology owners.
• Pediatric flavor platforms.
• Low-dead-space oral syringe manufacturers.
• Blow-fill-seal packaging providers.
• Antimicrobial container technologies.
• Particle-coating and controlled-dispersion platforms.
• Contract manufacturers with validated pediatric liquid capabilities.

The most attractive licensing structure would combine a formulation platform with a device or packaging right. An excipient-only license is less defensible because competitors can often substitute another permitted excipient.

What revenue exposure does the product have?

Exact product revenue is not generally disclosed separately from broader Advil or consumer-health sales. The economic exposure is tied to:

• Seasonal pediatric fever and pain demand.
• Brand share versus store brands.
• Retail pharmacy and mass-market shelf placement.
• E-commerce availability.
• Pediatric product line extensions.
• Price premiums for dye-free, sugar-free, preservative-free, or device-enhanced products.

A reformulated product can support a premium price only if the benefit is visible to caregivers. Better taste, smaller dose volume, cleaner excipient positioning, and lower dosing error are commercially stronger than technical claims that consumers cannot observe.

Key Takeaways

• Infants' Advil is a mature ibuprofen oral suspension with limited active-ingredient exclusivity.
• The core excipient challenge is maintaining a stable, redispersible suspension while masking ibuprofen bitterness.
• The strongest commercial opportunities are preservative-free packaging, sugar-free and dye-free positioning, improved taste masking, lower dosing volume, and integrated dosing devices.
• Conventional excipient combinations offer weak patent protection and are vulnerable to design-around.
• Device, packaging, particle-engineering, and manufacturing claims offer better patent leverage.
• Generic and private-label competition is structurally strong because ibuprofen is widely available under the OTC framework.
• FDA assessment must cover pediatric exposure, excipient concentration, microbial protection, stability, labeling, and dosing-device accuracy.

FAQs

Can Infants' Advil be reformulated without ibuprofen patent risk?

Yes. Ibuprofen is a mature active ingredient, so the principal risks concern formulation, labeling, manufacturing, trademarks, and device patents rather than molecule-level patent protection.

Is a sugar-free Infants' Advil formulation commercially attractive?

Yes, if the product preserves acceptable taste and suspension performance. Sugar removal alone is unlikely to justify a premium without a credible improvement in palatability or excipient profile.

Can a preservative-free ibuprofen suspension be sold in a multidose bottle?

Potentially, but the formulation and container-closure system would require validated microbial-control data. Unit-dose packaging is generally a more straightforward platform for a preservative-free claim.

Which excipient is most important for ibuprofen suspension stability?

The suspending and viscosity system is usually the central stability component. Its performance must be assessed with particle size, wetting, pH, preservative system, storage temperature, and dosing-device compatibility.

Are infant ibuprofen formulations eligible for biosimilar competition?

No. Ibuprofen is a small-molecule drug, not a biologic. Competition occurs through generic, OTC, private-label, and reformulated products rather than the biosimilar pathway.

References

1. DailyMed. (n.d.). Infants' Advil: Ibuprofen suspension, oral. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (2016). Use of inactive ingredients in pediatric drug products. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2024). Over-the-counter monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. https://www.accessdata.fda.gov/

5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm